Author Publications

2013

Steuten, L.M.G. and Wetering van de, G. and Groothuis-Oudshoorn, C.G.M. and Retel, V.P. (2013) A systematic and critical review of the evolving methods and applications of value of information in academia and practice. PharmacoEconomics, 31 . 25 - 48. ISSN 1170-7690

2012

Retel, V.P. and Joore, M.A. and Harten van, W.H. (2012) Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance. Breast cancer research and treatment, 131 (2). 627 - 636. ISSN 0167-6806

Retel, V.P. and Joore, M.A. and Rutgers, E.J. and Harten van, W.H. (2012) Scenario drafting to anticipate future developments in technology assessment. BMC research notes, 5 . p. 442. ISSN 1756-0500

2011

Retèl, Valesca P. and Molen van der, Lisette and Hilgers, Frans J.M. and Rasch, Coen R.N. and l'Ortye, Annemiek A.A.M.H.J. and Steuten, Lotte M.G. and Harten van, Wim H. (2011) A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy. BMC Cancer, 11 (475). ISSN 1471-2407

Retèl, Valesca P. and Rutgers, E.J.Th. and Joore, M.A. and Harten van, W.H. (2011) Establishing cost-effectiveness of genetic targeting of cancer therapies. European Journal of Oncology Pharmacy, 5 (1). pp. 28-31. ISSN 1783-3914

Retèl, Valesca Pavlawna (2011) Constructive technology assessment of gene expression profiling for breast cancer. thesis.

2010

Ploem, Martine Corrette and Retèl, Valesca P. and Linn, Sabine C. and Boven van, Hester H. and Schmidt, Marjanka K. and Jong de, Jean Philippe and Gevers, Joseph K.M. and Harten van, Wim H. (2010) Tumour tissue: who is in control? The Lancet Oncology, 11 (1). pp. 9-11. ISSN 1470-2045

Retèl, Valesca P. and Joore, Manuela A. and Knauer, Michael and Linn, Sabine C. and Hauptmann, Michael and Harten van, Wim H. (2010) Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. European Journal of Cancer, 46 (8). pp. 1382-1391. ISSN 0959-8049

2009

Retèl, V.P. and Rutgers, E.J. and Harten van, W.H. (2009) Scenarios as a tool for decision making in case of the 70-gene signature for breast cancer patients. In: 11th International St. Gallen Breast Cancer Conference, March 11-14, 2009, St. Gallen, Switzerland.

Retèl, Valesca and Joore, Manuela and Harten van, Wim (2009) Scenario drafting as a tool to perform early cost-effectiveness analyses: the case of the 70-genes prognosis signature in breast cancer: Oral presentations. In: 7th World Congress on Health Economics, 12-15 July 2009, Beijing, China.

Retèl, Valesca P. and Bueno-de-Mesquita, Jolien M. and Hummel, Marjan J.M. and Vijver van de, Marc J. and Douma, Kirsten F.L. and Karsenberg, Kim and Dam van, Frits S.A.M. and Krimpen van, Cees and Bellot, Frank E. and Roumen, Rudi M.H. and Linn, Sabine C. and Harten van, Wim H. (2009) Constructive Technology Assessment (CTA) as a tool in Coverage with Evidence
Development: the case of the 70-gene prognosis signature for breast cancer diagnostics. International Journal of Techology Assessment in Health Care, 25 (1). pp. 73-83. ISSN 0266-4623

Retèl, Valesca P. and Hummel, Marjan J.M. and Harten van, Wim (2009) Review on early technology assessments of nanotechnologies in oncology. Molecular Oncology, 3 (5-6). pp. 394-401. ISSN 1574-7891

2008

Knauer, Michael and Retèl, V. and Bueno-de-Mesquita, J.M. and Rutgers, E.J.T. and Harten van, W.H. and Rodenhuis, S. and Vijver van de, M.J. and Veer van 't, L.J. and Linn, S.C. (2008) Benefit of the 70-gene profile for widely used guidelines: an answer to increased selection for adjuvant chemotherapy in breast cancer (Poster). In: CTRC-AACR 31st Annual San Antonio Breast Cancer Symposium, December 10-14, 2008, San Antonio, TX, USA.

Retèl, V.P. and Bueno-de-Mesquita, J.M. and Veer van 't, L. and Vijver van de, M.J. and Hummel, M.J.M. and Linn, S.C. and Harten van, W.H. (2008) Implementation assessment of the 70-gene prognosis signature for breast cancer diagnostics (Poster). In: ASCO Annual Meeting 2008, May 30 - June 3, 2008, Chicago, IL, USA.

Retèl, Valesca P. and Hummel, Marjan J.M. and Harten van, Willem H. (2008) Early phase Technology Assessment of nanotechnology in oncology. Tumori, 94 (2). pp. 284-290. ISSN 0300-8916

Retèl, Valesca P. and Rutgers, E.J.Th. and Joore, M.A. and Harten van, W.H. (2008) Establishing cost-effectiveness of genetic targeting of cancer therapies. EJHP Practice, 14 (6). pp. 52-54. ISSN 1781-9989